Menu
AstraZeneca headquarters
AstraZeneca will discontinue a certain bottle dosage of its breast cancer drug Truqap (capiversatib) by the end of the year but allow 340B covered entities to replenish their supply with an equivalent dose in blister pack package form.

AstraZeneca Tightens Contract Pharmacy Restrictions to Require Claims Data Submission

Bella Czajkowski, National Correspondent 340B Report Views
Beginning Oct. 1, AstraZeneca will tighten its 340B contract pharmacy restrictions to require claims data on 340B utilization at contract [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.

Post Navigation

ACA Played Key Role in 340B Growth, Drug Industry Consulting Firm Finds

How to Leverage AI for Enhanced 340B Program Management: Learn More and Ask Your Questions on 9/24 at 1:00PM ET

Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Quick verification required before signup

Site Footer Live